Aytu BioPharma (AYTU) Competitors $2.42 +0.14 (+5.90%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$2.42 0.00 (0.00%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. IGMS, INCR, IMUX, ICCC, BMEA, STRO, ADAP, SKYE, IKNA, and CLSDShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include IGM Biosciences (IGMS), InterCure (INCR), Immunic (IMUX), ImmuCell (ICCC), Biomea Fusion (BMEA), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Skye Bioscience (SKYE), Ikena Oncology (IKNA), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors IGM Biosciences InterCure Immunic ImmuCell Biomea Fusion Sutro Biopharma Adaptimmune Therapeutics Skye Bioscience Ikena Oncology Clearside Biomedical IGM Biosciences (NASDAQ:IGMS) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Do analysts rate IGMS or AYTU? IGM Biosciences presently has a consensus target price of $5.50, indicating a potential upside of 305.90%. Aytu BioPharma has a consensus target price of $10.00, indicating a potential upside of 312.37%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IGMS or AYTU? In the previous week, Aytu BioPharma had 2 more articles in the media than IGM Biosciences. MarketBeat recorded 8 mentions for Aytu BioPharma and 6 mentions for IGM Biosciences. IGM Biosciences' average media sentiment score of 0.46 beat Aytu BioPharma's score of 0.45 indicating that IGM Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IGM Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aytu BioPharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in IGMS or AYTU? 42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by company insiders. Comparatively, 3.6% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, IGMS or AYTU? Aytu BioPharma has higher revenue and earnings than IGM Biosciences. Aytu BioPharma is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.68M30.22-$195.79M-$3.27-0.41Aytu BioPharma$81M0.27-$15.84M-$0.72-3.37 Which has more volatility & risk, IGMS or AYTU? IGM Biosciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Is IGMS or AYTU more profitable? Aytu BioPharma has a net margin of 2.37% compared to IGM Biosciences' net margin of -7,417.79%. Aytu BioPharma's return on equity of 3.51% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-7,417.79% -317.97% -71.43% Aytu BioPharma 2.37%3.51%0.91% SummaryAytu BioPharma beats IGM Biosciences on 10 of the 16 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.41M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-3.3721.5627.4320.23Price / Sales0.27281.76422.11118.64Price / CashN/A42.7336.8958.07Price / Book0.527.518.045.67Net Income-$15.84M-$55.05M$3.18B$249.13M7 Day Performance15.48%4.61%2.89%3.28%1 Month Performance62.75%4.72%3.70%5.56%1 Year Performance-15.27%5.92%36.15%21.12% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma3.7032 of 5 stars$2.43+5.9%$10.00+312.4%-14.9%$21.41M$81M-3.37160Analyst ForecastIGMSIGM Biosciences4.428 of 5 stars$1.16-0.9%$5.50+374.1%-79.0%$69.94M$2.68M-0.35190News CoverageNegative NewsINCRInterCure0.475 of 5 stars$1.52+0.3%N/A-30.0%$69.27M$66.28M0.00350Gap UpIMUXImmunic2.8609 of 5 stars$0.71-1.7%$11.60+1,538.4%-36.3%$68.99MN/A-0.5870Positive NewsICCCImmuCell0.3055 of 5 stars$6.65-12.5%N/A+56.9%$68.68M$26.49M-94.9970News CoverageGap UpHigh Trading VolumeBMEABiomea Fusion2.5937 of 5 stars$1.69-6.6%$21.40+1,166.3%-62.0%$68.01MN/A-0.4850STROSutro Biopharma3.2211 of 5 stars$0.80-0.3%$6.11+665.4%-73.4%$67.64M$62.04M-0.27240ADAPAdaptimmune Therapeutics2.3073 of 5 stars$0.24-4.2%$1.52+526.4%-75.4%$67.06M$178.03M-0.90490SKYESkye Bioscience2.5342 of 5 stars$2.87+66.0%$16.60+478.2%-38.7%$66.90MN/A-3.5011IKNAIkena Oncology2.4238 of 5 stars$1.34-1.5%$3.00+123.9%-18.4%$65.63M$9.16M-1.5670Positive NewsCLSDClearside Biomedical1.4352 of 5 stars$0.82-2.3%$4.80+485.1%-35.3%$65.26M$1.66M-2.0030 Related Companies and Tools Related Companies IGM Biosciences Alternatives InterCure Alternatives Immunic Alternatives ImmuCell Alternatives Biomea Fusion Alternatives Sutro Biopharma Alternatives Adaptimmune Therapeutics Alternatives Skye Bioscience Alternatives Ikena Oncology Alternatives Clearside Biomedical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
